ADB-CHMINACA
|
ADB-CHMINACA
N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide MAB-CHMINACA |
|
| N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide | |
| Synthetic cannabinoids | |
| Synthetic cannabinoid receptor agonists |
|
|
|
InChI=1S/C21H30N4O2/c1-21(2,3)18(19(22)26)23-20(27)17-15-11-7-8-12-16(15)25(24-17)13-14-9-5-4-6-10-14/h7-8,11-12,14,18H,4-6,9-10,13H2,1-3H3,(H2,22,26)(H,23,27)
|
|
ZWCCSIUBHCZKOY-UHFFFAOYSA-N
|
|
|
O=C(C1=NN(CC2CCCCC2)C3=C1C=CC=C3)NC(C(N)=O)C(C)(C)C
|
|
| C21H30N4O2 | |
| 370.4885 g/mol | |
| 71/II | |
| 2019 | |
|
This substance is included in Schedule II of the 1971 Convention on Psychotropic Substances. |